Coagulation disorders and thromboembolic disease in COVID-19 : Review of current evidence in search of a better approach
García-Ortega, A. (Instituto de Investigación Sanitaria La Fe)
de la Rosa Carrillo, David (Institut d'Investigació Biomèdica Sant Pau)
Oscullo, G. (Instituto de Investigación Sanitaria La Fe)
Castillo, Diego (Institut d'Investigació Biomèdica Sant Pau)
López-Reyes, R. (Instituto de Investigación Sanitaria La Fe)
Martínez-García, Miguel Ángel (Instituto de Investigación Sanitaria La Fe)

Date:	2021
Abstract:	The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an unprecedented global health problem, causing more than 20 million infections and more than 900,000 deaths (September 2020). The SARS-CoV-2 infection, known as COVID-19, has various clinical presentations, from asymptomatic or mild catarrhal processes to severe pneumonia that rapidly progresses to acute respiratory distress syndrome (ARDS) and multiple organ failure. In the last few months, much scientific literature has been devoted to descriptions of different aspects of the coagulation disorders and arterial and venous thrombotic complications associated with COVID-19, particularly venous thromboembolism (VTE). These studies have revealed that SARS-CoV-2 could lead to a prothrombotic state reflecting the high cumulative incidence of associated thrombotic events, particularly in patients admitted to intensive care units (ICUs). As regards the coagulopathy observed in association with SARS-CoV-2 infection, the mechanisms that activate coagulation have been hypothesized as being linked to immune responses, through the release of pro-inflammatory mediators that interact with platelets, stimulate the expression of tissue factor, induce an upregulation of plasminogen activator inhibitor-1, suppress the fibrinolytic system and lead to endothelial dysfunction, triggering thrombogenesis. D-dimer elevation has been recognized as a useful biomarker of poor prognosis, although the best cut-off point for predicting VTE in COVID-19 patients has still not been clarified. This review will try to update all the available scientific information on this important topic with enormous clinical and therapeutic implications.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Pulmonary embolism (PE) ; Coronavirus disease 2019 (COVID-19) ; D-dimer ; Thrombosis ; Inflammation
Published in:	Journal of Thoracic Disease, Vol. 13 Núm. 2 (february 2021) , p. 1239-1255, ISSN 2077-6624

DOI: 10.21037/JTD-20-3062
PMID: 33717596

17 p, 533.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles